Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Down 37.9% in February

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a large decrease in short interest in February. As of February 27th, there was short interest totaling 304,069 shares, a decrease of 37.9% from the February 12th total of 489,419 shares. Based on an average daily trading volume, of 167,556 shares, the short-interest ratio is presently 1.8 days. Currently, 4.7% of the company’s stock are sold short. Currently, 4.7% of the company’s stock are sold short. Based on an average daily trading volume, of 167,556 shares, the short-interest ratio is presently 1.8 days.

Analysts Set New Price Targets

Several brokerages have weighed in on AMIX. Weiss Ratings reissued a “sell (e+)” rating on shares of Autonomix Medical in a report on Wednesday, January 21st. Maxim Group cut their price objective on shares of Autonomix Medical from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Autonomix Medical has a consensus rating of “Hold” and a consensus price target of $2.00.

Autonomix Medical Trading Up 0.7%

Shares of NASDAQ:AMIX opened at $0.43 on Friday. Autonomix Medical has a twelve month low of $0.34 and a twelve month high of $2.82. The company has a market cap of $2.94 million, a PE ratio of -0.12 and a beta of -2.80. The company’s 50 day moving average is $0.43 and its 200 day moving average is $0.78.

Autonomix Medical (NASDAQ:AMIX) last announced its quarterly earnings data on Wednesday, February 11th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.10. Equities research analysts predict that Autonomix Medical will post -10 earnings per share for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.